Page 581 - Read Online

Cordover et al. J Cancer Metastasis Treat 2020;6:45 I http://dx.doi.org/10.20517/2394-4722.2020.101 Page 17 of 19

2001;61:4892-900.
50. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively
inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-40.
51. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert
Rev Anticancer Ther 2011;11:263-75.
52. Yakes FM, Chinratanalab W, Ritter RA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and
Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
53. Parra-Palau JL, Morancho B, Peg V, et al. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. J Natl Cancer
Inst 2014;106:dju291.
54. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
55. Scaltriti M, Chandarlapaty S, Prudkin L, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor
receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010;16:2688-95.
56. Collins DM, Conlon NT, Kannan S, et al. Preclinical characteristics of the irreversible Pan-HER kinase inhibitor neratinib compared with
lapatinib: implications for the treatment of HER2-positive and HER2-mutated breast cancer. Cancers (Basel) 2019;11:737.
57. Saura C, Oliveira M, Feng YH, et al; NALA Investigators. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive
metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 2020;38:3138-49.
58. Nagy P, Friedländer E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-
expressing breast cancer cell line. Cancer Res 2005;65:473-82.
59. Gu S, Hu Z, Ngamcherdtrakul W, et al. Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 2016;7:14727-41.
60. Faltus T, Yuan J, Zimmer B, et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-
overexpressing breast cancer cells. Neoplasia 2004;6:786-95.
61. Gu S, Ngamcherdtrakul W, Reda M, Hu Z, Gray JW, Yantasee W. Lack of acquired resistance in HER2-positive breast cancer cells after
long-term HER2 siRNA nanoparticle treatment. PLoS One 2018;13:e0198141.
62. Ortega MA, Fraile-Martínez O, Asúnsolo Á, Buján J, García-Honduvilla N, Coca S. Signal transduction pathways in breast cancer: the
important role of PI3K/Akt/mTOR. J Oncol 2020;2020:9258396.
63. Jean S, Kiger AA. Classes of phosphoinositide 3-kinases at a glance. J Cell Sci 2014;127:923-8.
64. Papa A, Pandolfi PP. The PTEN-PI3K axis in cancer. Biomolecules 2019;9:153.
65. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012;13:1886-918.
66. Chamcheu JC, Roy T, Uddin MB, et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review
of current status and future trends on natural and synthetic agents therapy. Cells 2019;8:803.
67. Luo Y, Xu W, Li G, Cui W. Weighing in on mTOR Complex 2 signaling: the expanding role in cell metabolism. Oxid Med Cell Longev
2018;2018:7838647.
68. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
69. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006;59:557-63.
70. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer
is associated with tumour progression. Breast Cancer Res 2005;7:R788-95.
71. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 2010;347: 21-41.
72. Hyman DM, Smyth LM, Donoghue MTA, et al. AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol 2017;35:2251-9.
73. Grabiner BC, Nardi V, Birsoy K, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict
rapamycin sensitivity. Cancer Discov 2014;4:554-63.
74. Akinleye A, Avvaru P, Furqan M, Song YP, Liu DL. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol
Oncol 2013;6:88.
75. Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase
inhibitor. Mol Cancer Ther 2012;11:317-28.
76. Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities
in tumor cell lines and xenograft models. Mol Cancer Ther 2013;12:2319-30.
77. Hanker AB, Kaklamani V, Arteaga CL. Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in
solid tumors. Cancer Discov 2019;9:482-91.
78. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer
2019;18:26.
79. Wang X, Ding J, Meng LH. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin
2015;36:1170-6.
80. Fritsch C, Huang A, Chatenay-Rivauday C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and
development of the patient stratification strategy for clinical trials. Mol Cancer Ther 2014;13:1117-29.
81. Zhou W, Guo S, Liu M, Burow ME, Wang G. Targeting CXCL12/CXCR4 Axis in tumor immunotherapy. Curr Med Chem
2019;26:3026-41.
82. Schwartz S, Wongvipat J, Trigwell CB, et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective
inhibition of PI3Kβ. Cancer Cell 2015;27:109-22.
83. Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol 2019;21:63-71.
84. Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 2019;20:755.